Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

REFERENCES

• Braun A. H., Achterrath W., Wilke H., Vanhoefer U., Harstrick A., Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004; 100(8)1558–1577, [CSA]
   PubMed Web of Science ®Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer Irinotecan Study Group. N. Engl. J. Med. 2000; 343(13)905–914, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldberg R. M., Sargent D. J., Morton R. F., Fuchs C. S., Ramanathan R. K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2004; 22(1)23–30, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Bosset J. F., Milan C., Rougier P., Bouché O., et al. Randomized trial comparing monthly low-dose LV and fluorouracil bolus with bimonthly high-dose LV and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 1997; 15(2)808–815, [CSA]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000; 18(16)2938–2947, [CSA]
   PubMed Web of Science ®Google Scholar
• Andre T., Bensmaine M. A., Louvet C., Francois E., Lucas V., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999; 17(11)3560–3568, [CSA]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Vignoud J., Tournigand C., Louvet C., André T., et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer 1997; 33(2)214–219, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Douillard J. Y., Cunningham D., Roth A. D., Navarro M., James R. D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355(9212)1041–1047, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• André T., Louvet C., Maindrault-Goebel F., Couteau C., Mabro M., et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur. J. Cancer 1999; 35(9)1343–1347, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tournigand C., André T., Achille E., Lledo G., Flesh M., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 2004; 22(2)229–237, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cassidy J., Misset J. L. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 2002; 29(5)11–20, Suppl 15[CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47(1)207–214, [CSA]
   PubMed Web of Science ®Google Scholar
• Caussanel J. P., Lévi F., Brienza S., Misset J. L., Itzhaki M., et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 1990; 82(12)1046–1050, [CSA]
   PubMed Web of Science ®Google Scholar
• Andre T., Bensmaine M. A., Louvet C., Francois E., Lucas V., et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J. Clin. Oncol. 1999; 17(11)3560–3568, [CSA]
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481, [CSA]
   Web of Science ®Google Scholar
• Bleiberg H., Hendlisz A. Advanced colorectal cancer treatment in Europe: what have we achieved?. Anticancer Drugs 2002; 13(5)461–471, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ryan D. P., Clark J. W., Kulke M. H., Fuchs C. S., Earle C. C., et al. A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. Cancer Invest. 2003; 21(4)505–511, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• de Gramont A., Cervantes A., André T., Figer A., Lledo G., et al. Optimox study: FOLFOX 7/ LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2005; 22(14s), Abstr. 3525[CSA]
   Google Scholar
• Cascinu S., Catalano V., Cordella L., Labianca R., Giordani P., et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2002; 20(16)3478–3483, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Penz M., Kornek G. V., Raderer M., Ulrich-Pur H., Fiebiger W., et al. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann. Oncol. 2001; 12(3)421–422, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 2004; 10(12)4055–4061, Part 1[CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gamelin E., Gamelin L., Bossi L., Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 2002; 29(5)21–33, Suppl. 15[CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wilson R. H., Lehky T., Thomas R. R., Quinn M. G., Floeter M. K., et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J. Clin. Oncol. 2002; 20(7)1767–1774, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., Louvet C., André T., Carola E., Lotz J. P., et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX-6). Eur. J. Cancer 1999; 35(9)1338–1342, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Maindrault-Goebel F., de Gramont A., Louvet C., André T., Carola E., et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX-7). Eur. J. Cancer 2001; 37(8)1000–1005, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hsieh R. K., Chao T. Y., Chen W. S., Yang T. S., Chen L. T., et al. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest. 2004; 22(2)171–179, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pitot H. C., Rowland K. M., Sargent D. J., Philip P. A., Mitchell E. P., et al. N9841: a randomized phase III equivalence trial of irinotecan versus oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced colorectal cancer previously treated with 5-FU. Proc. Am. Soc. Clin. Oncol. 2005; 22(14s), Abstr. 3506[CSA]
   Google Scholar
• Seymour M. T., For the UK NCRI Colorectal Clinical Studies Group. Fluorouracil, oxaliplatin and CPT-11, use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 2005; 22(14s), Abstr. 3518[CSA]
   Google Scholar
• Rosati G., Tucci A., Rinaldi A., Colarusso D., Pizza C., et al. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. Oncology 2004; 66(5)371–378, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Becouarn Y., Gamelin E., Coudert B., Négrier S., Pierga J. Y., et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J. Clin. Oncol. 2001; 19(22)4195–4201, [CSA]
   PubMed Web of Science ®Google Scholar
• Taieb J., Artru P., Paye F., Louvet C., Perez N., et al. Intensive chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J. Clin. Oncol. 2005; 23(3)502–509, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350(23)2335–2342, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351(4)337–345, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Iqbal S., Stoehlmacher J., Lenz H. J. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest. 2004; 22(5)762–773, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar